April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Intralesional OK-432 (Picibanil) Sclerosing Agent in the Treatment of Orbital Lymphangiomas
Author Affiliations & Notes
  • Imtiaz A Chaudhry
    Houston Oculoplastics Associates, Memorial Herman Med Plaza TX Med Ctr, Houston, TX
  • Fahad Al-Saikhan
    Ophthalmology, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • Osama Al-Sheikh
    Ophthalmology, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • Waleed Al-Rashed
    Ophthalmology, Al-Imam Muhammad ibn Saud Islamic University, Faculty of Medicine, Riyadh, Saudi Arabia
  • Farrukh A Shamsi
    Ophthalmology, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • Yonca O Arat
    Ophthalmology, Guven Hospital, Ankara, Turkey
  • Milton Boniuk
    Ophthalmology, Baylor College of Medicine, Houston, TX
  • Footnotes
    Commercial Relationships Imtiaz Chaudhry, None; Fahad Al-Saikhan, None; Osama Al-Sheikh, None; Waleed Al-Rashed, None; Farrukh Shamsi, None; Yonca Arat, None; Milton Boniuk, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4081. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Imtiaz A Chaudhry, Fahad Al-Saikhan, Osama Al-Sheikh, Waleed Al-Rashed, Farrukh A Shamsi, Yonca O Arat, Milton Boniuk; Intralesional OK-432 (Picibanil) Sclerosing Agent in the Treatment of Orbital Lymphangiomas. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4081.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Periocular lymphangioma is the 2nd most common vascular tumor after capillary hemangioma clinically apparent during the early years of childhood. Over the years, different sclerosing agents have been utilized with limited success. Our initial experience suggested that OK-432 (Picibanil) may be useful in the treatment of lymphangiomas in the orbital region. The purpose of this study is to report our experience with intra-lesional OK-432 for the treatment of orbital lymphangiomas.


A prospective, interventional case series of 12 patients with orbital lymphangiomas was conducted to asses efficacy of OK-432 regarding its use in the stabilizing or reduction of the tumor after intralesional administration. Demographic of these patients along with their response to the treatment was studied.


There were 9 patients (6 female, average age 9.5 years, range 1.6 to 25 years, 5 right side) who required an average of 2.2 injections (range 1-4) over a one month to 12 month period. Two patients had diffuse orbital hemorrhage in the cystic spaces after being discharged on the same day following interalesional OK-432 injections. With an average follow-up of 6.4 months (range 1.5 to 13 months), 8 patients (88.9%) showed either regression of the tumor size or resulted in stabilizing its further growth. Seven (87.5%) patients also showed partial to moderate response by improved vision, decreasing pain, or proptosis. One patient with a large cystic lesion did not benefit from the injection and required surgical excision.


This prospective study suggests that intra-lesional OK-432 may have beneficial effect in the control of orbital lymphangioma. Further larger well-controlled studies may be helpful to elucidate the long-term effect of the OK-432 sclerosing agent. Suzuki Y, Obana A, Gohto Y, Miki T, Otuka H, Inoue Y. Management of orbital lymphangioma using intralesional injection of OK-432. Br J Ophthalmol. 2000;84:614-7. Yoon JS, Choi JB, Kim SJ, Lee SY. Intralesional injection of OK-432 for vision-threatening orbital lymphangioma. Graefes Arch Clin Exp Ophthalmol. 2007;245:1031-5. Oyama T, Eguchi K, Cho H, Abe H. A variety of orbital lymphangioma treatments: one case treated with orbital decompression therapy and the other case with intralesional injection of OK-432 therapy. Nippon Ganka Gakkai Zasshi. 2009;113:732-40.

Keywords: 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 631 orbit • 744 tumors  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.